Legend Biotech shares fall 16% after first earnings report under new CEO
Published . Updated .
Key takeaways
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
This report is about pharma and health.
Directly affected
- LEGN Legend Biotech
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “biotech” (pharma and health) in this story.
- XBI SPDR S&P Biotech ETF
SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “biotech” (pharma and health) in this story.
- LLY Eli Lilly and
Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “biotech” (pharma and health) in this story.
- JNJ Johnson & Johnson
Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “biotech” (pharma and health) in this story.
- PFE Pfizer
Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “biotech” (pharma and health) in this story.
- MRK Merck
Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “biotech” (pharma and health) in this story.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| LEGN | +11.92% | +15.02% | base | -5.33% | after close | after close | after close |
| XLV | +0.42% | -2.16% | base | -0.91% | after close | after close | after close |
| XBI | +2.62% | -1.83% | base | +0.25% | after close | after close | after close |
| LLY | -1.00% | -5.42% | base | -1.01% | after close | after close | after close |
| JNJ | -1.58% | -1.58% | base | -1.24% | after close | after close | after close |
| PFE | +4.87% | +0.09% | base | -0.54% | after close | after close | after close |
| MRK | +1.60% | -0.83% | base | -1.52% | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Legend Biotech shares fall 16% after first earnings report under new CEO Fierce Pharma
Source: Fierce Pharma
Price since this story was published: Select Sector Spdr Tr (XLV)
| Company | When | Move | Status |
|---|---|---|---|
| Johnson & Johnson (JNJ) | that day | -1.24% | still updating |
| Johnson & Johnson (JNJ) | three days earlier | -1.58% | final price |
| Johnson & Johnson (JNJ) | five days earlier | -1.58% | final price |
| LEGN | that day | -5.33% | still updating |
| LEGN | three days earlier | +15.02% | final price |
| LEGN | five days earlier | +11.92% | final price |
| Eli Lilly (LLY) | that day | -1.01% | still updating |
| Eli Lilly (LLY) | three days earlier | -5.42% | final price |
| Eli Lilly (LLY) | five days earlier | -1.00% | final price |
| Merck (MRK) | that day | -1.52% | still updating |
| Merck (MRK) | three days earlier | -0.83% | final price |
| Merck (MRK) | five days earlier | +1.60% | final price |
| Pfizer (PFE) | that day | -0.54% | still updating |
| Pfizer (PFE) | three days earlier | +0.09% | final price |
| Pfizer (PFE) | five days earlier | +4.87% | final price |
| Spdr Series Trust (XBI) | that day | +0.25% | still updating |
| Spdr Series Trust (XBI) | three days earlier | -1.83% | final price |
| Spdr Series Trust (XBI) | five days earlier | +2.62% | final price |
| Select Sector Spdr Tr (XLV) | that day | -0.91% | still updating |
| Select Sector Spdr Tr (XLV) | three days earlier | -2.16% | final price |
| Select Sector Spdr Tr (XLV) | five days earlier | +0.42% | final price |
Trades by members of Congress and officials in the stocks in this story
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 68 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Johnson & Johnson (JNJ) (held by a spouse), worth $15,001 - $50,000 on 7 Oct 2026. That is 35 days before publication. Filed 5 Nov 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 30 Sep 2026. That is 42 days before publication. Filed 30 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 47 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Pfizer (PFE) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 68 days before publication. Filed 7 Oct 2026. View the filing.
- Donald J Trump, an executive branch official, bought Pfizer (PFE), worth $100,001 - $250,000 on 21 Aug 2026. That is 82 days before publication. Filed 8 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 48 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar bought Merck (MRK), worth $15,001 - $50,000 on 19 Aug 2026. That is 84 days before publication. Filed 9 Sep 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Select Sector Spdr Tr (XLV)
Companies tied to this story
- XLV Select Sector Spdr Tr
Select Sector Spdr Tr (XLV) is linked, with no stored direction, medium confidence in the 11 Nov 2026 story “Legend Biotech shares fall 16% after first earnings report under new CEO.” Reason on file: Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “biotech” (pharma and health) in this story
- XBI Spdr Series Trust
For “Legend Biotech shares fall 16% after first earnings report under new CEO,” Spdr Series Trust (XBI) is linked, with no stored direction, medium confidence. Reason on file: SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “biotech” (pharma and health) in this story
- LLY Eli Lilly
Eli Lilly (LLY) is linked, with no stored direction, medium confidence in the 11 Nov 2026 story “Legend Biotech shares fall 16% after first earnings report under new CEO.” Reason on file: Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “biotech” (pharma and health) in this story
- JNJ Johnson & Johnson
Johnson & Johnson (JNJ) is linked, with no stored direction, medium confidence in the 11 Nov 2026 story “Legend Biotech shares fall 16% after first earnings report under new CEO.” Reason on file: Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “biotech” (pharma and health) in this story
- PFE Pfizer
In “Legend Biotech shares fall 16% after first earnings report under new CEO,” Pfizer (PFE) is linked, with no stored direction, medium confidence. Reason on file: Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “biotech” (pharma and health) in this story
- MRK Merck
In “Legend Biotech shares fall 16% after first earnings report under new CEO,” Merck (MRK) is linked, with no stored direction, medium confidence. Reason on file: Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “biotech” (pharma and health) in this story
Select Sector Spdr Tr (XLV)
Select Sector Spdr Tr (XLV) is the company in “Legend Biotech shares fall 16% after first earnings report under new CEO,” the 11 Nov 2026 this story story.
What ties Select Sector Spdr Tr (XLV) to the headline is this: Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “biotech” (pharma and health) in this story
Spdr Series Trust (XBI) is here too. Its reason reads: SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “biotech” (pharma and health) in this story
Dates and price levels for Select Sector Spdr Tr (XLV)
LLY traded between 1176.87 and 1452.66 across 20 sessions. The latest close on file is 1433.04.
How strong the case is around Select Sector Spdr Tr (XLV)
46 out of 100Price not final
“Legend Biotech shares fall 16% after first earnings report under new CEO” scores 46 out of 100. The score uses 1 sources, and 6 linked companies. The price is not final yet.